Those gains over January, when the drugs fell to third and fourth on the list, came even as spending dropped for both meds: AbbVie spent $34.8 million on Rinvoq’s TV ads and $27 million on ...

Patients in the EU with giant cell arteritis (GCA), an inflammation of the arteries, could soon have the first oral targeted treatment for the disease after AbbVie's Rinvoq was recommended for ...

Rinvoq (upadacitinib) is not safe to take while pregnant or breastfeeding. Certain factors, such as the form of Rinvoq you’re prescribed, may determine whether you should take the drug during ...

Rinvoq (upadacitinib) is a prescription drug that works to treat certain inflammatory conditions by decreasing the activity of immune system cells. Your response to this drug may vary based on ...

RINVOQ is approved in the European Union (EU) for the treatment of adults with radiographic axial spondylarthritis, nonradiographic axial spondylarthritis, psoriatic arthritis, rheumatoid ...